目的 观察枢瑞（国产托瑞米芬）治疗乳腺增生病的临床疗效及安全性。方法 从我院门诊患者中选取符合条件的患者50例，口服枢瑞40mg／d，饭后服药，至下次月经来潮，经期停药。治疗3个疗程。观察治疗前后，疗效、血清性激素及血脂；肝功能：SCOT、SGPT；血脂变化；B超、钼靶片、CT检查腺体厚度、结构等变化。结果 总有效率为90％，明显促进腺体退化；并能调整机体内源性激素水平，改善乳腺慢性增生的病变过程。结论 托瑞米芬治疗乳腺增生病安全有效。
Objective To observe the therapeutic effect and side effects of Toremifene（TOR）in women with hyperplasia of mammary gland （HMG） and meanwhile test blood sex hormones and blood lipid levels. Methods 50 severe FIMG patients（age range 34 - 50 years）with a mean age of 43.6 years, were selected from outpatient service of our section during November, 2004 to November,2005. TOR 40mg/d was taken orally after dinner, total course lasting 3 months but no medication during menstruation. Clinical observation including therapeutic effect, sex hormone level, serum lipid level, liver function, thickness of mammary gland, constitution of the gland, etc. were also made before and after the treatment. Results TOR could not only cure HMG, but also regulate sex hormone secretion in HMG patients. Clinical study showed that the total effective rate was 90 %, with a significant difference in comparing with the control group, （ P 〈 0.05） ; while progestogen and testosterone increased significantly （P 〈 0.05） ; but no significantly change of follicle stimulating hormone and luteinizing hormone was found. TOR showed marked effect in treating and preventing HMG, it could modulate sex hormone, and improve the construction of mammary gland. Toremifene decreased cholesterol and LDL cholesterol and triglyceride levels by 9.0 %, 10.1% and 9.7 % respectively. Conclusion TOR is an effective agent in the treatment of HMG, and accelerate the deterioration of mammary gland significantly. TOR can adjust the endogenous sex hormone level, delay the development of chronic serious hyperplasia of mammary gland. TOR also improves all lipoproteius that are associated with increased coronary heart disease （CHD）risk.
Journal of Tongji University(Medical Science)
hyperplasia of mammary gland